QTNT - Quotient Limited
| Previous Close | 8.75 |
| Open | 8.60 |
| Bid | 8.51 x 1400 |
| Ask | 8.52 x 1100 |
| Day's Range | 8.47 - 8.72 |
| 52 Week Range | 5.52 - 11.15 |
| Volume | 36,516 |
| Avg. Volume | 346,860 |
| Market Cap | 566.162M |
| Beta (3Y Monthly) | 0.65 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.92 |
| Earnings Date | Aug 7, 2017 - Aug 11, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.17 |
- GlobeNewswire•12 days ago
Quotient Limited to Participate in the Raymond James Life Sciences and MedTech Conference
JERSEY, Channel Islands, June 05, 2019 -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company’s Chief Financial Officer,.
- Simply Wall St.•19 days ago
How Does Quotient Limited (NASDAQ:QTNT) Affect Your Portfolio Volatility?
Anyone researching Quotient Limited (NASDAQ:QTNT) might want to consider the historical volatility of the share price...
- Thomson Reuters StreetEvents•20 days ago
Edited Transcript of QTNT earnings conference call or presentation 28-May-19 12:00pm GMT
Q4 2019 Quotient Ltd Earnings Call
Motley Fool•20 days agoQuotient Ltd (QTNT) Q4 2019 Earnings Call Transcript
QTNT earnings call for the period ending March 31, 2019.
- Associated Press•20 days ago
Quotient: Fiscal 4Q Earnings Snapshot
The Eysins, Jersey-based company said it had a loss of 41 cents per share. The blood test developer posted revenue of $8.3 million in the period. For the year, the company reported that its loss widened ...
- GlobeNewswire•20 days ago
Quotient Limited Recaps Recent Milestone Achievement and Updates on the Initial Serological Disease Screening CE Mark Submission, planned 2019 US Field Trials and Reports Record Financial Results
CE mark received on the initial Immunohematology microarray in April 20192018 manufacturing site certification and MosaiQ™ device CE mark combine with the recent approval to.
- GlobeNewswire•27 days ago
Quotient Limited to Participate in the Jefferies 2019 Healthcare Conference
JERSEY, Channel Islands, May 21, 2019 -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company’s Chief Financial Officer,.
- Zacks•27 days ago
Quotient (QTNT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Quotient (QTNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire•27 days ago
Quotient Ltd. Announces FDA Approval of Seven Additional Blood Bank Reagents
Quotient Limited (QTNT), an established, commercial-stage diagnostics company (the Company), today announced the U.S. Food and Drug Administration (FDA) has approved the commercialization of seven additional blood bank reagents for extended antigen typing, completing the Company’s core product offering to the US market. In March 2018, seven Quotient reagents were also approved by the FDA, including two market firsts. “Quotient has more than tripled our FDA approved product offering since coming directly to market in the U.S. We continue to be motivated to bring high-quality, customer-friendly products to the U.S. market, and are sincerely grateful to our customers for their ongoing support,” said Bill Brady, VP US Commercial at Quotient.
- GlobeNewswire•last month
Quotient Limited to Report Fiscal Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call
JERSEY, Channel Islands, May 14, 2019 -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal fourth.
- Insider Monkey•last month
Hedge Funds Have Never Been More Bullish On Quotient Limited (QTNT)
Hedge funds are not perfect. They have their bad picks just like everyone else. Facebook, a stock hedge funds have loved, lost nearly 40% of its value at one point in 2018. Although hedge funds are not perfect, their consensus picks do deliver solid returns, however. Our data show the top 15 S&P 500 stocks […]
- GlobeNewswire•2 months ago
Quotient Limited Receives European CE Mark for its Initial IH Microarray
Quotient Limited (QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced receipt of the CE Mark (Conformité Européenne) for its initial Immunohematology (IH) Microarray for use with its CE Marked MosaiQTM diagnostic platform. Following the successful conclusion of its first EU field trial in July 2018 and the subsequent submission of the technical dossier for CE Mark approval in late September 2018, on April 30, 2019, the Company was informed that it had received CE Mark clearance for its initial IH Microarray for use in transfusion diagnostics.
- GlobeNewswire•2 months ago
Quotient Limited Announces Initial SDS EU Field Trial Performance Data for MosaiQ™
Quotient Limited (QTNT), a commercial-stage diagnostics company (the Company), today reported positive EU field trial performance data for its initial MosaiQ™ Serological Disease Screening (SDS) Microarray. Field trial results for the initial MosaiQ SDS Microarray used for the detection of CMV and Syphilis achieved the required clinical performance. The field trial data was obtained by donor center testing laboratories using microarrays manufactured in Quotient’s ISO audited manufacturing facility and run on the CE marked MosaiQ instrument.
- Simply Wall St.•2 months ago
Can You Imagine How Chuffed Quotient's (NASDAQ:QTNT) Shareholders Feel About Its 113% Share Price Gain?
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Unless you borrow money to invest, the potential losses are limited. But if you pick the right business to buy shar...
- GlobeNewswire•3 months ago
Quotient Limited to Participate in the Cowen and Company 39th Annual Health Care Conference
JERSEY, Channel Islands, March 07, 2019 -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company’s Chief Financial Officer,.
- Simply Wall St.•4 months ago
How Much Are Quotient Limited (NASDAQ:QTNT) Insiders Spending On Buying Shares?
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! We've lost count of how many times insiders have accumulatedRead More...
- GlobeNewswire•4 months ago
Quotient Limited to Host Investor Day and Ring Closing Bell at the NASDAQ on March 4, 2019
Quotient Limited (QTNT), a commercial-stage diagnostics company, today announced that the Company will host an Investor Day on Monday, March 4, 2019 from 1:00pm – 3:00pm ET, in New York, NY. Following the Investor Day, the Company’s Chief Executive Officer, Franz Walt, will ring the Closing Bell of the NASDAQ Stock Exchange.
- GlobeNewswire•4 months ago
Quotient Limited to Participate in the 8th Annual SVB Leerink Global Healthcare Conference
JERSEY, Channel Islands, Feb. 15, 2019 -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that today announced that the Company’s Chief.
- Thomson Reuters StreetEvents•4 months ago
Edited Transcript of QTNT earnings conference call or presentation 31-Jan-19 1:30pm GMT
Q3 2019 Quotient Ltd Earnings Call
Motley Fool•4 months agoQuotient Ltd (QTNT) Q3 2019 Earnings Conference Call Transcript
QTNT earnings call for the period ending December 31, 2018.
- Zacks•5 months ago
Quotient (QTNT) Reports Q3 Loss, Tops Revenue Estimates
Quotient (QTNT) delivered earnings and revenue surprises of -12.20% and 8.44%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•5 months ago
Quotient: Fiscal 3Q Earnings Snapshot
On a per-share basis, the Eysins, Jersey-based company said it had a loss of 46 cents. The blood test developer posted revenue of $6.7 million in the period. Quotient shares have risen 31 percent since ...
- GlobeNewswire•5 months ago
Quotient Limited Provides an Update on Extended Immunohematology Microarray Performance and on the Commencement of the Initial Serological Disease Screening Field Trial together with Third Quarter Fiscal 2019 Results
Development data provides positive results for extended IH microarray panelField trial for initial Serological Disease microarray panel has commenced Reagent revenue growth of.
- GlobeNewswire•5 months ago
Quotient Limited to Report Fiscal Third Quarter 2019 Financial Results and Host Conference Call
JERSEY, Channel Islands, Jan. 17, 2019 -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal third.
